Due to the great expectation on novel targeting agents in advanced endometrial cancer, new drugs against specific molecular pathways with particular focus on PI3KCA/AKT/mTOR axis are emerging as promising treatments for endometrial cancer with aggressive phenotype [1]. This evidence concerns the gene AKT1 and endometrial cancer.